Exploring CYP2J2: lipid mediators, inhibitors and therapeutic implications
- 1 September 2020
- journal article
- review article
- Published by Elsevier in Drug Discovery Today
- Vol. 25 (9) , 1744-1753
Abstract
No abstract availableKeywords
Funding Information
- Deutsche Forschungsgemeinschaft
This publication has 85 references indexed in Scilit:
- Effects of Ellagic Acid on Angiogenic Factors in Prostate Cancer CellsCancers, 2013
- Characterization of Four New Mouse Cytochrome P450 Enzymes of the CYP2J SubfamilyDrug Metabolism and Disposition, 2013
- Identifying a Selective Substrate and Inhibitor Pair for the Evaluation of CYP2J2 ActivityDrug Metabolism and Disposition, 2012
- Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in miceJournal of Clinical Investigation, 2012
- Cytochrome P450 2J2 Is Highly Expressed in Hematologic Malignant Diseases and Promotes Tumor Cell GrowthThe Journal of Pharmacology and Experimental Therapeutics, 2011
- The ω‐3 epoxide of eicosapentaenoic acid inhibits endothelial cell proliferation by p38 MAP kinase activation and cyclin D1/CDK4 down‐regulationBritish Journal of Pharmacology, 2010
- Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseasesNature Reviews Drug Discovery, 2009
- Selective Inhibitors of CYP2J2 Related to Terfenadine Exhibit Strong Activity against Human Cancers in Vitro and in VivoThe Journal of Pharmacology and Experimental Therapeutics, 2009
- Membrane lipids: where they are and how they behaveNature Reviews Molecular Cell Biology, 2008
- Selective, competitive and mechanism-based inhibitors of human cytochrome P450 2J2Archives of Biochemistry and Biophysics, 2007